Antiviral Treatments - 27/09/17
Résumé |
Most viral respiratory tract infections are caused by classic respiratory viruses, including influenza, respiratory syncytial virus, human metapneumovirus, parainfluenza, rhinovirus, and adenovirus, whereas other viruses, such as herpes simplex, cytomegalovirus, and measles virus, can opportunistically affect the respiratory tract. The M2 inhibitors, amantadine and rimantadine, were historically effective for the prevention and treatment of influenza A but all circulating strains are currently resistant to these drugs. Neuraminidase inhibitors are the sole approved class of antivirals to treat influenza. Ribavirin, especially when combined with intravenous antibody, reduces morbidity and mortality among immunosuppressed patients.
Le texte complet de cet article est disponible en PDF.Keywords : Respiratory virus, Influenza, Respiratory syncytial virus (RSV), Neuraminidase inhibitor, Ribavirin
Plan
| Disclosure Statement: M.G. Ison has received research support, paid to Northwestern University, from Alios, Astellas, Beckman Coulter, Chimerix, Gilead, Jansen/Johnson & Johnson; he has provided compensated consultation to Celltrion, Chimerix, Farmark, Genentech/Roche, Toyama/MediVector, and Shionogi, and uncompensated consultation to BioCryst, Biota, Cellex, GlaxoSmithKlein, Romark, NexBio, Theraclone, Unither Virology, and Vertex; he is also a paid member of data and safety monitor boards related to research activity conducted by Astellas, Jansen/Vertex. |
Vol 38 - N° 1
P. 139-153 - mars 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?

